Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib

Xueqian Gong(Eli Lilly (United States)), Lacey M. Litchfield(Eli Lilly (United States)), Yue Webster(Eli Lilly (United States)), Li-Chun Chio(Eli Lilly (United States)), Swee Seong Wong(Eli Lilly (United States)), Trent R. Stewart(Eli Lilly (United States)), Michele Dowless(Eli Lilly (United States)), Jack Dempsey(Eli Lilly (United States)), Yi Arial Zeng(Eli Lilly (United States)), Raquel Torres(Eli Lilly (Spain)), Karsten Boehnke(Eli Lilly (Spain)), Cecilia Mur(Eli Lilly (Spain)), Carlos Marugán(Eli Lilly (Spain)), Carmen Baquero(Eli Lilly (Spain)), Chunping Yu(Lilly (China)), Steven M. Bray(Eli Lilly (United States)), Isabella H. Wulur(Eli Lilly (United States)), Bi Chen(Eli Lilly (United States)), Shaoyou Chu(Eli Lilly (United States)), Hui-Rong Qian(Eli Lilly (United States)), Philip W. Iversen(Eli Lilly (United States)), Farhana F. Merzoug(Eli Lilly (United States)), Xiang S. Ye(Lilly (China)), Christoph Reinhard(Eli Lilly (United States)), Alfonso de Dios(Eli Lilly (United States)), Jian Du(Eli Lilly (United States)), Charles W. Caldwell(Eli Lilly (United States)), Marı́a José Lallena(Eli Lilly (Spain)), Richard P. Beckmann(Eli Lilly (United States)), Sean G. Buchanan(Eli Lilly (United States))
Cancer Cell
December 1, 2017
Cited by 236Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis